Citations

Showing 10 of 108119 citations.

Acute leukemias harboring KMT2A/MLLT10 fusion: a 10‐year experience from a single genomics laboratory
Peterson, Jess F. , Sukov, William R. , Pitel, Beth A. , Smoley, Stephanie A., Pearce, Kathryn E., Meyer, Reid G., Williamson, Cynthia M., Smadbeck, James B. , Vasmatzis, George , Hoppman, Nicole L., Greipp, Patricia T. , Peterson, Jess F , Pitel, Beth A , Greipp, Patricia T , Baughn, Linda B. , Ketterling, Rhett P.

Mayo Clinic

Genes, Chromosomes and Cancer | February 1, 2019 | Volume: 58 | Issue: 8 | Pages: 567-577

10.1002/gcc.22741 | PMID 30707474 Get It

ABSTRACTThe MLLT10 (formerly AF10) gene is the fourth most common KMT2A fusion partner across all acute leukemias and requires at least 3 breaks to form an in‐frame KMT2A/MLLT10 fusion due to the opposite orientation of each gene. A 10‐year retrospective review was performed to identify individuals from all age groups that harbor KMT2A/MLLT10 fusion obtained by our KMT2A/MLLT10 dual‐color dual‐fusion fluorescence in situ hybridization (D‐FISH) assay. Of the 60 unique individuals identified, 31 were male and 29 were female (M:F ratio, 1.1:1) with ages ranging from 3 days to 86 years (mean 21.5 years, median 5.5 years). The diagnoses included acute myeloid leukemia (AML) (49 patients, 82%), B‐ or T‐lymphoblastic leukemia/lymphoma (7 patients, 12%), myeloid sarcoma (3 patients, 5%), and a single case (2%) of undifferentiated leukemia. Twenty‐seven of 49 patients (55%) with AML were in the infant or pediatric age group. Fifty‐three of 60 patients (88%) had KMT2A/MLLT10 D‐FISH signal patterns mostly consisting of single fusions. In addition, 10 (26%) of 38 patients with conventional chromosome studies had “normal” (5 patients) or abnormal (5 patients) chromosome studies that lacked structural or numeric abnormalities involving chromosomes 10 or 11, implying cryptic cytogenetic mechanisms for KMT2A/MLLT10 fusion. Lastly, mate‐pair sequencing was performed on 4 AML cases, 2 of which had “normal” chromosome studies and cryptic KMT2A/MLLT10 fusion as detected by KMT2A/MLLT10 D‐FISH studies, and verified the multiple breaks required to generate KMT2A/MLLT10 fusion.
Arterial Pseudoaneurysm following Radiotherapy in Patients with a History of Nasopharyngeal Carcinoma
Tangbumrungtham, Navarat , Dodd, Robert , Patel, Zara M. , Patel, Zara , Choby, Garret

Mayo Clinic

OTO Open | February 1, 2019 | Volume: 3 | Issue: 1 | Pages: No page available

10.1177/2473974x18823002 | PMID 31236534 Get It

Uncommon Intraluminal Tumors of the Gallbladder and Biliary Tract: Spectrum of Imaging Appearances
Chatterjee, Argha , Vendrami, Camila Lopes , Bandy, Andrew , Menias, Christine O. , Hammond, Nancy A., Yaghmai, Vahid , Miller, Frank H. , Lopes Vendrami, Camila, Nikolaidis, Paul, Mittal, Pardeep K, Bandy, Andrew J, Yang, Guang-Yu, Miller, Frank H , Nikolaidis, Paul , Mittal, Pardeep Kumar , Yang, Guang‐Yu

Mayo Clinic

RadioGraphics | February 1, 2019 | Volume: 39 | Issue: 2 | Pages: 388-412

10.1148/rg.2019180164 | PMID 30707646 Get It

A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study
Partridge, Ann H. , Ruddy, Kathryn J. , Barry, William T., Ligibel, Jennifer A. , Sprunck‐Harrild, Kim , Rosenberg, Shoshana M. , Baker, Emily, Hoverman, J. Russell , Emmons, Karen M. , Partridge, Ann H , Greaney, Mary L.

Mayo Clinic

Cancer | February 1, 2019 | Volume: 125 | Issue: 11 | Pages: 1799-1806

10.1002/cncr.31984 | PMID 30707756 Get It

Background The authors conducted a cluster randomized study to determine the effect of an exportable educational intervention for young women with breast cancer (YWI) on improving care. Methods Sites were randomized 1:1 to the YWI or a contact time control physical activity intervention (PAI) stratified by academic or community site. Up to 15 women aged ≤45 years with newly diagnosed breast cancer were enrolled at each of 14 academic sites and 10 were enrolled at each of 40 community sites. The primary endpoint, attention to fertility, was ascertained by medical record review. Statistical inferences concerning the effect of the intervention used general estimating equations for clustered data. Results A total of 467 patients across 54 sites were enrolled between July 2012 and December 2013. The median age of the patients at the time of diagnosis was 40 years (range, 22‐45 years). Attention to fertility by 3 months was observed in 55% of patients in the YWI and 58% of patients in the PAI ( P = .88). Rates were found to be strongly correlated with age ( P < .0001), and were highest in patients aged <30 years. Attention to genetics was similar (80% in the YWI and 81% in the PAI), whereas attention to emotional health was higher in patients in the YWI (87% vs 76%; estimated odds ratio, 2.63 [95% confidence interval, 1.20‐5.76; P = .016]). Patients rated both interventions as valuable in providing education (64% in the YWI and 63% in the PAI). Conclusions The current study failed to demonstrate differences in attention to fertility with an intervention to improve care for women with breast cancer, although attention to fertility was found to be higher than expected in both groups and emotional health was improved in the YWI group. Greater attention to young women with breast cancer in general may promote more comprehensive care for this population.
Metabolic Syndrome Interferes with Packaging of Proteins within Porcine Mesenchymal Stem Cell-Derived Extracellular Vesicles
Eirin, Alfonso , Zhu, Xiang-Yang, Woollard, John R. , Dasari, Surendra , Lerman, Lilach O. , Lerman, Lilach O , Eirin, Alfonso , Tang, Hui Ru , Lerman, Amir

Mayo Clinic

Stem Cells Translational Medicine | February 1, 2019 | Volume: 8 | Issue: 5 | Pages: 430-440

10.1002/sctm.18-0171 | PMID 30707002 Get It

Abstract Mesenchymal stem/stromal cells (MSCs) release extracellular vesicles (EVs), which shuttle proteins to recipient cells, promoting cellular repair. We hypothesized that cardiovascular risk factors may alter the pattern of proteins packed within MSC-derived EVs. To test this, we compared the protein cargo of EVs to their parent MSCs in pigs with metabolic syndrome (MetS) and Lean controls. Porcine MSCs were harvested from abdominal fat after 16 weeks of Lean- or MetS-diet (n = 5 each), and their EVs isolated. Following liquid chromatography mass spectrometry proteomic analysis, proteins were classified based on cellular component, molecular function, and protein class. Five candidate proteins were validated by Western blot. Clustering analysis was performed to identify primary functional categories of proteins enriched in or excluded from EVs. Proteomics analysis identified 6,690 and 6,790 distinct proteins in Lean- and MetS-EVs, respectively. Differential expression analysis revealed that 146 proteins were upregulated and 273 downregulated in Lean-EVs versus Lean-MSCs, whereas 787 proteins were upregulated and 185 downregulated in MetS-EVs versus MetS-MSCs. Proteins enriched in both Lean- and MetS-EVs participate in vesicle-mediated transport and cell-to-cell communication. Proteins enriched exclusively in Lean-EVs modulate pathways related to the MSC reparative capacity, including cell proliferation, differentiation, and activation, as well as transforming growth factor-β signaling. Contrarily, proteins enriched only in MetS-EVs are linked to proinflammatory pathways, including acute inflammatory response, leukocyte transendothelial migration, and cytokine production. Coculture with MetS-EVs increased renal tubular cell inflammation. MetS alters the protein cargo of porcine MSC-derived EVs, selectively packaging specific proinflammatory signatures that may impair their ability to repair damaged tissues. Stem Cells Translational Medicine 2019;8:430–440
Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma
Atkins, Isabelle, Kinnersley, Ben , Ostrom, Quinn T. , Labrèche, Karim , Il’yasova, Dora , Armstrong, Georgina , Eckel‐Passow, Jeanette E. , Schoemaker, Minouk J. , Nöthen, Markus M. , Barnholtz‐Sloan, Jill S. , Simon, Matthias , Rajaraman, Preetha , Shildkraut, Joellen, Bernstein, Jonine L. , Jöckel, Karl‐Heinz, Lai, Rose , Claus, Elizabeth B. , Johansen, Christoffer , Wrensch, Margaret , Melin, Beatrice , Jenkins, Robert B. , Sanson, Marc , Bondy, Melissa L. , Houlston, Richard S. , Swerdlow, Anthony J , Houlston, Richard S , Barnholtz-Sloan, Jill S , Nöthen, Markus M , Sanson, Marc , Schoemaker, Minouk J , Armstrong, Georgina , Swerdlow, Anthony J. , Chanock, Stephen Jacob , Hoffmann, Per , Olson, Sara H. , Ostrom, Quinn T

Mayo Clinic

Cancer Research | February 1, 2019 | Volume: 79 | Issue: 8 | Pages: 2065-2071

10.1158/0008-5472.can-18-2888 | PMID 30709929 Get It

Abstract Genome-wide association studies (GWAS) have so far identified 25 loci associated with glioma risk, with most showing specificity for either glioblastoma (GBM) or non-GBM tumors. The majority of these GWAS susceptibility variants reside in noncoding regions and the causal genes underlying the associations are largely unknown. Here we performed a transcriptome-wide association study to search for novel risk loci and candidate causal genes at known GWAS loci using Genotype-Tissue Expression Project (GTEx) data to predict cis-predicted gene expression in relation to GBM and non-GBM risk in conjunction with GWAS summary statistics on 12,488 glioma cases (6,183 GBM and 5,820 non-GBM) and 18,169 controls. Imposing a Bonferroni-corrected significance level of P &lt; 5.69 × 10−6, we identified 31 genes, including GALNT6 at 12q13.33, as a candidate novel risk locus for GBM (mean Z = 4.43; P = 5.68 × 10−6). GALNT6 resides at least 55 Mb away from any previously identified glioma risk variant, while all other 30 significantly associated genes were located within 1 Mb of known GWAS-identified loci and were not significant after conditioning on the known GWAS-identified variants. These data identify a novel locus (GALNT6 at 12q13.33) and 30 genes at 12 known glioma risk loci associated with glioma risk, providing further insights into glioma tumorigenesis. Significance: This study identifies new genes associated with glioma risk, increasing understanding of how these tumors develop.
Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases
Lac, Vivian , Billadeau, Daniel D. , Borgida, Ayelet , Gallinger, Steven , Lucien, Fabrice , Leong, Hon S.

Mayo Clinic

Oncotarget | February 1, 2019 | Volume: 10 | Issue: 10 | Pages: 1045-1055

10.18632/oncotarget.26620 | PMID 30800217 Get It

Radiopathological correlation of a von Hippel-Lindau syndrome associated pancreatic neuroendocrine tumour with clear cell features
Hopp, Alix C., Collins, Joseph M. , Nguyen, Cuong C. , Yang, Ming

Mayo Clinic

BMJ Case Reports | February 1, 2019 | Volume: 12 | Issue: 2 | Pages: bcr-2018-227891

10.1136/bcr-2018-227891 | PMID 30709893 Get It

Marked responses to pemetrexed chemotherapy for metastatic adenocarcinoma of the parotid gland: Case series
Viscuse, Paul V. , Price, Katharine A. , Price, Katharine

Mayo Clinic

Head & Neck | February 1, 2019 | Volume: 41 | Issue: 6 | Pages: No page available

10.1002/hed.25658 | PMID 30706564 Get It

AbstractBackgroundThere are no proven systemic therapies for metastatic adenocarcinoma of the salivary glands. Pemetrexed use in adenocarcinoma of the salivary glands has not been previously described.MethodsRetrospective case reports and literature review.ResultsTwo patients with metastatic salivary gland adenocarcinoma were treated with single‐agent pemetrexed with marked response and clinical benefit. Case 1 describes a sustained clinical response for 8 months after failing several lines of chemotherapy. Case 2 describes a marked interval response of diffuse metastatic disease at 2 months with resolution of bone pain and sustained response at 8 months.ConclusionTo our knowledge, this is the first report of efficacy of single‐agent pemetrexed for metastatic salivary gland adenocarcinoma. Given the significant and sustained responses in heavily pretreated patients, further investigation of pemetrexed for salivary cancer may be warranted.
Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer
Kłubo-Gwieździńska, Joanna , Auh, Sungyoung , Gershengorn, Marvin C. , Daley, Brianna, Burman, Kenneth D. , Wartofsky, Leonard , Urken, Mark L. , Dewey, Eliza H., Smallridge, Robert C., Chindris, Ana-Maria, Kebebew, Electron , Smallridge, Robert, Bikas, Athanasios , Chindris, Ana-Maria

Mayo Clinic

JAMA Network Open | February 1, 2019 | Volume: 2 | Issue: 2 | Pages: e187754

10.1001/jamanetworkopen.2018.7754 | PMID 30707227 Get It